Immudex’s Post

Periods of fasting reprogram the #immunesystem's natural killer cells to better fight #cancer, according to a new study in mice from researchers at Memorial Sloan Kettering Cancer Center (MSK). #Fasting and other dietary regimens are increasingly being explored as ways to starve cancer cells of the nutrients they need to grow and to make cancer treatments more effective. Now a team of researchers from MSK's Sloan Kettering Institute and their collaborators have shown for the first time that fasting can reprogram the #metabolism of natural killer cells, helping them to survive in the harsh environment in and around #tumors, while also improving their cancer-fighting ability. The study, led by postdoctoral fellow Rebecca Delconte, Ph.D., was published in #Immunity. The findings could help explain one of the mechanisms by which fasting may help the body defend against cancer—along with more generally reducing fat and improving metabolism. And while more research is needed, the results also suggest fasting could be a strategy to improve immune responses to make #immunotherapy more effective. Tumors take up essential nutrients, creating a hostile environment often rich in lipids that are detrimental to most immune cells. The study showed that fasting reprograms these natural killer cells to better survive in this suppressive environment. More information: Rebecca B. Delconte et al, Fasting reshapes tissue-specific niches to improve NK cell-mediated anti-tumor immunity, Immunity (2024). https://lnkd.in/e4ajhWak https://lnkd.in/e_HHkqUH

🙌 🙌 Topic: #Tumor #microenvironment and immunology of #cholangiocarcinoma Team: University of Padua and Yale School of Medicine Read more: https://lnkd.in/gDbXD7th ✔ In this review, the team described the cell populations within the TME, in particular those involved in the innate and adaptive immune response and how they interact with tumor cells and with matrix proteins. The TME is crucial for #CCA to mount an immune escape response and is the battlefield where molecularly targeted therapies and immune therapy, particularly in combination, may actually prove their therapeutic value. Welcome to read and share it with your colleagues! Nuh Rahbari Zobair Younossi Orpheus Kolokythas Orpheus Kolokythas Nada KILANI Sasaki Kazunari XC Li David TOUGERON Ayoub Aomari Cataldo Doria, MD, PhD, MBA, FACS

New research from the Icahn School of Medicine at Mount Sinai directly captured tumor microenvironment immune dynamics in the largest study of patients with relapsed/refractory multiple myeloma to date. The study analyzed the pharmacodynamic effects of iberdomide, an immunomodulatory therapy, to determine therapeutic efficacy and assist in establishing combination strategies using this treatment. The team developed and used a large-scale mass cytometry panel for immunophenotyping of bone marrow samples, correlating findings to disease characteristics, prior therapy, and a peripheral blood immune phenotype. Van Oekelen, O. et al. 2024: https://lnkd.in/gHdNVmNE #immunotherapy #cancerresearch #CyTOF

I was deeply engrossed in the brilliant book "The Song of the Cell" by Siddhartha Mukherjee, one of the world's foremost scientific historians, while simultaneously working with my lab colleagues Jeremy Baldwin, Christoph Heuser-Loy, and Dragana Slavkovic Lukic to understand how mitochondria traverse nanotubes between mesenchymal stromal cells and CD8+ T cells, enhancing their antitumor immunity. Suddenly, I paused at this powerful passage in the book: "In 2010, when Emily Whitehead received her infusion of CAR T cells, or twelve years later, when the first patients with sickle cell anemia are surviving, disease-free, with gene-modified blood stem cells, we are transitioning from the century of the gene to a contiguous, overlapping century of the cell" (p. 10). The century of the cell is not yet complete, but we are already delving into its smaller compartments, witnessing the dawn of the "contiguous, overlapping century of the organelle." Richard Feynman famously said, "There's plenty of room at the bottom!"—a statement made in reference to physics, but equally relevant to cell biology. In our group, led by the exceptional Luca Gattinoni, Jeremy Baldwin and our team are breaking new ground in this field, demonstrating the antitumor power of organelle-enhanced CD8+ T cells. https://lnkd.in/gKwR8CMq #immunotherapy #immunology #cancer #mitochondria #nanotube #Tcells

🔬✨ The #TNF (Tumour Necrosis Factor) superfamily is a group of #proteins that play a crucial role in various physiological processes, including immune regulation, cell survival, and inflammation. Understanding the importance of the TNF superfamily is essential for researchers, clinicians, and professionals in the biomedical field. The TNF superfamily of #cytokines represents a multifunctional group of pro-inflammatory cytokines which activate #signallingpathways for #cellsurvival, #apoptosis, #inflammatoryresponses, and #cellulardifferentiation.  Understanding and harnessing the potential of this superfamily can lead to ground-breaking advancements in #immunotherapy, #cancer research, and the #treatment of #inflammatory and #autoimmune #diseases. For all our #PeproTech/ #ThermoFisherScientific's HIGH #QUALITY and HIGHLY #CITED #cytokines / #growthfactors, visit https://lnkd.in/ddE8vQcy Feel free to reach out to me directly on LinkedIn or to your local Thermo Fisher Scientific Representative! We would be more than happy to support you. 😊 #TNFSuperfamily #Immunology #cytokines #growthfactors #chemokines #CancerResearch #Inflammation #expertise #quality #reliability

#Bcells | A #Metabolic Dependency of #EBV can be Targeted (through #IDO1) to Hinder #Transformation | First Release Science Magazine Study Posits New Therapy Approach to #Cancer #Lymphoma #AutoImmuneDisease #MS 👏 | Following infection of B cells, Epstein Barr virus (EBV) engages host pathways that mediate cell proliferation and transformation, contributing to the propensity of the virus to drive immune dysregulation and lymphomagenesis. Here* Bojana Müller-Durovic et al found that the EBV protein EBNA2 initiates NAD de novo biosynthesis by driving expression of the metabolic enzyme IDO1 in infected B cells. Virus-enforced NAD production sustained mitochondrial complex I activity, to match ATP-production with bioenergetic requirements of proliferation and transformation. In transplant patients, IDO1 expression in EBV-infected B cells, and a serum signature of increased IDO1 activity, preceded development of lymphoma. In humanized mice infected with EBV, IDO1 inhibition reduced both viremia and lymphomagenesis. Virus-orchestrated NAD biosynthesis is, thus, a druggable metabolic vulnerability of EBV-driven B cell transformation—opening therapeutic possibilities for EBV-related diseases. *https://lnkd.in/eZA9JAEz Celentyx Ltd Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady Lawrence Young FIGURE | Metabolic profiling of EBV-infected B cells reveals transient up-regulation of NAD de novo biosynthesis in newly infected B cells |

From May 12th to 15th, 2025, the 3rd Electronic Conference on Biomedicines will take place. I am honored to chair Session S4: Immune System, Tumor Immunology, and Autoimmune Disease. https://lnkd.in/dEV-94ej Biomedicines MDPI #immunesystem #autoimmunity #rheumatoidarthritis #tumorimmunology #conference #research #immunology #immunomics

Happy #ImmunologyDay!🧬🔬 Did you know that we have millions of different #antibodies, but each #𝐰𝐡𝐢𝐭𝐞 𝐛𝐥𝐨𝐨𝐝 𝐜𝐞𝐥𝐥 in our immune system produces 𝒐𝒏𝒍𝒚 𝒐𝒏𝒆 𝒌𝒊𝒏𝒅 of antibody? In 1975 Georges Köhler and Cesar Milstein developed a method to fuse a 𝐧𝐨𝐫𝐦𝐚𝐥 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲-𝐩𝐫𝐨𝐝𝐮𝐜𝐢𝐧𝐠 𝐜𝐞𝐥𝐥 𝐰𝐢𝐭𝐡 𝐚 𝐭𝐮𝐦𝐨𝐮𝐫 𝐜𝐞𝐥𝐥, forming a #hybrid that was both #immortal and could create a specific antibody. Their hybrid cell could produce antibodies of the same type – #monoclonal antibodies – in whatever quantities are needed for research and medicine.💡 The production of monoclonal antibodies has enabled researchers to improve tests for 𝐢𝐧𝐟𝐞𝐜𝐭𝐢𝐨𝐮𝐬 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬, design completely new therapeutic strategies for diseases such as 𝐜𝐚𝐧𝐜𝐞𝐫, better explain the mechanisms behind 𝐚𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐞 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬 and suppress rejection in organ #transplants among other breakthroughs.🌍 While the market for monoclonal antibodies is now worth #billions of dollars, Köhler and Milstein did not patent their technique or benefit financially by forming a company, instead remaining in 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡. Köhler shared the 1983 #NobelPrize in Physiology or Medicine with Niels K. Jerne and César Milstein.🏆 https://lnkd.in/gTggq2_t Image: 𝐀𝐧𝐭𝐢-𝐂𝐚𝐧𝐜𝐞𝐫 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬. Small chemical ornaments (cones) slow the release of anti-cancer antibodies (blue) from this functionalised mesoporous silica (orange). Springer Medizin Österreich #ImmunologyDay #MonoclonalAntibodies #ScientificInnovation

In previous posts, we explored how radiation, particularly charged particles, modulates the immune response by stimulating both the innate and adaptive immune systems. These findings were based on an in vitro study using the Merkel Cell Carcinoma (MCC) cell line exposed to different radiation qualities under well-oxygenated conditions (normoxia). However, one may ask: How does hypoxia modulate the immune response? Before delving deeper, it is well-established that the oxygen enhancement ratio (OER) for photon irradiation is approximately 3. This means that the dose required to induce the same biological effect in hypoxic conditions is about three times higher than that in normoxic conditions. Further, hypoxia is associated with poor prognosis and is strongly associated with genetic instability, metastasis, immune suppression, and radioresistance during radiotherapy (RT failure) resulting in a more clinically aggressive phenotype. But how exactly does hypoxia influence the immune response, and what mechanisms are involved?

Overcome the limitations in cellular modelling of human diseases with IPSCs... It is no doubt that developing cellular models for human diseases in vitro can be a challenging task. As highlighted in a Nature review article by Cerneckis et al, Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications, this task would require access to large quantities of cells. While some cell types can be easily isolated from living donors, for other types of cells such as brain and heart cells, they are largely unavailable. To combat this, many use rodent cells as the alternative. But these cells differ substantially to human cells and may not reflect certain human-specific cellular behaviors that would make the models relevant to human disease. We were excited to see how IPSCs were mentioned as key to overcoming the above limitations as they can be readily differentiated into hard-to-access cell types that possess human-specific phenotypes which are both physiologically and genetically relevant to the human disease model of interest. At Axol, we are committed to supporting the development of advanced in vitro systems from human donors to functional iPSC-derived cells that can be used for research, toxicity studies and drug discovery. Our axoCells can be used to build IPSC models of neurodegenerative diseases (such as Alzheimer's Disease, ALS, and Huntington's disease) as well as cardiac diseases (including arrythmias) that retain behaviors of the disease state! Click here to read the full paper: https://hubs.la/Q02PszbC0 If you would like to find out more about how our axoCells™ can help you develop better disease models, contact us at operations@axolbio.com You can also find out more about our products that meet your research needs in our catalog, click here to download the full catalog: https://hubs.la/Q02Ps7C60 #Humandiseasemodelling #biopharma #iPSC #StemCells